Correction to: British Journal of Cancer (2007) 96, 16–20. doi: 10.1038/6603520
The authors would like to note that the preliminary results of a phase II clinical trial of sorafenib in patients with metastatic thyroid cancer reported as a personal communication in the manuscript have been previously presented as part of the following two abstract presentations:
Kloos R, Ringel M, Knopp M, Heverhagen J, Hall N Weldy L, Arbogast D, Collamore M, Shah M (2005). Preliminary results of Phase II clinical trial of RAF/VEGF-R kinase inhibitor, BAY 43-9006 (sorafenib), in metastatic thyroid carcinoma. Thyroid. 2005 Abstracts from International Thyroid Congress, Vol 15, No. S1:S-22.
Kloos R, Ringel M, Knopp M, Heverhagen J, Rittenberry J, Weldy L, Arbogast D, Collamore M, King M, Young D, Shah M (2006). Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY-439006 in patients with metastatic papillary thyroid carcinoma (PTC): Updated results of a phase II study. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings, Part I, Vol 24, No. 18S:5534.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Additional information
The online version of the original article can be found at 10.1038/sj.bjc.6603520
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Espinosa, A., Porchia, L. & Ringel, M. Erratum: Targeting BRAF in thyroid cancer. Br J Cancer 96, 1313 (2007). https://doi.org/10.1038/sj.bjc.6603676
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6603676
